New drug plus chemo for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced (Stage IIIB/IIIC or IV) squamous non-small cell lung cancer that cannot be removed by surgery and is not suitable for chemoradiation.
- You must not have had any previous cancer treatment for this lung cancer.
- Your cancer must be measurable on a scan (not in the brain).
- You must not have certain gene mutations (EGFR, ALK, ROS1, BRAF) that can be treated with targeted pills.
- You must be willing to provide a tumor sample for PD-L1 testing and have good organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new combination of drugs (one that targets cancer cells and another that boosts the immune system) against a standard chemotherapy plus immune therapy combination. The goal is to see if the new approach works better as a first treatment for advanced squamous lung cancer.
This trial tests a new combination of drugs (BL-B01D1 plus a bispecific antibody) against the current standard chemotherapy and immunotherapy. It aims to see if the new combination works better for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before.
This study tests a new combination treatment (SCTB41 plus docetaxel) for people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy and an anti-angiogenesis drug (rh-endostatin) for people with advanced or recurrent squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Double Blind trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.